Final answer:
The primary risk with the therapeutic use of ES cells is rejection.
Step-by-step explanation:
The primary risk with the therapeutic use of ES cells is rejection. Embryonic stem cells are seen as foreign by the patient's immune system, which may trigger rejection. This poses a significant obstacle to the application of cell-based therapy using ES cells.